Home LiteratureArticle Details
PMID: 11698589 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Martín-Aparicio E, Yamamoto A, Hernández F, Hen R, Avila J, Lucas JJ

Abstract

Neuronal intranuclear inclusions are a histopathological hallmark of Huntington's disease. Nevertheless, the precise mechanism by which they are formed and their relevance to neuronal cell death and/or dysfunction remains unclear. We recently generated a conditional mouse model of Huntington's disease (HD94) in which silencing expression of mutated huntingtin led to the disappearance of intranuclear aggregates and amelioration of the behavioral phenotype. Here, we analyze primary striatal neuronal cultures from HD94 mice to explore the dynamics of aggregate formation and reversal, the possible mechanisms involved, and the correlation between aggregates and neuronal death. In parallel, we examine symptomatic adult HD94 mice in similar studies and explored the relationship between aggregate clearance and behavioral reversal. We report that, in culture, aggregate formation and reversal were rapid processes, such that 2 d of transgene expression led to aggregate formation, and 5 d of transgene suppression led to aggregate disappearance. In mice, full reversal of aggregates and intranuclear mutant huntingtin was more rapid than reported previously and preceded the motor recovery by several weeks. Furthermore, the proteasome inhibitor lactacystin inhibited the aggregate clearance observed in culture, thus indicating that aggregate formation is a balance between the rate of huntingtin synthesis and its degradation by the proteasome. Finally, neither expression of the mutant huntingtin nor aggregates compromised the viability of HD94 cultures. This correlated with the lack of cell death in symptomatic HD94 mice, thus demonstrating that neuronal dysfunction, and not cell loss, triggered by mutant huntingtin underlies symptomatology.

MeSH Terms
Acetylcysteine/analogs & derivatives,pharmacology Animals Behavior, Animal/drug effects Cell Death/drug effects,genetics Cell Survival/drug effects,genetics Cells, Cultured Corpus Striatum/drug effects,metabolism,pathology Cysteine Endopeptidases/drug effects,metabolism Disease Models, Animal Gene Silencing/drug effects Genes, Dominant Huntingtin Protein Huntington Disease/genetics,metabolism,pathology Locomotion/drug effects,genetics Macromolecular Substances Mice Mice, Neurologic Mutants Multienzyme Complexes/antagonists & inhibitors,drug effects,metabolism Nerve Tissue Proteins/antagonists & inhibitors,genetics,metabolism Neurons/drug effects,metabolism,pathology Nuclear Proteins/antagonists & inhibitors,genetics,metabolism Phenotype Proteasome Endopeptidase Complex Remission Induction Tetracycline/pharmacology Transgenes Ubiquitin/metabolism
Chemicals
Htt protein, mouse Huntingtin Protein Macromolecular Substances Multienzyme Complexes Nerve Tissue Proteins Nuclear Proteins Ubiquitin lactacystin Cysteine Endopeptidases Proteasome Endopeptidase Complex Tetracycline Acetylcysteine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Martín-Aparicio E
Centro de Biologia Molecular "Severo Ochoa," Consejo Superior de Investigaciones Cientificas-Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Yamamoto A
Hernández F
Hen R
Avila J
Lucas J J
References (50)
50 references, click to expand
  1. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.
    Exp Neurol. 1999 Mar;156(1):92-9 PMID: 10192780
  2. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.
    Exp Neurol. 2001 Jun;169(2):340-50 PMID: 11358447
  3. Reversing neurodegeneration: a promise unfolds.
    Cell. 2000 Mar 31;101(1):1-4 PMID: 10778849
  4. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
    J Neurosci. 1999 Feb 1;19(3):964-73 PMID: 9920660
  5. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.
    Cell. 1998 Oct 2;95(1):55-66 PMID: 9778247
  6. Homozygotes for Huntington's disease.
    Nature. 1987 Mar 12-18;326(6109):194-7 PMID: 2881213
  7. Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains.
    Neurobiol Dis. 1994 Dec;1(3):159-66 PMID: 9173995
  8. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice.
    Hum Mol Genet. 1999 Jul;8(7):1227-36 PMID: 10369868
  9. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.
    EMBO J. 2001 Jan 15;20(1-2):27-39 PMID: 11226152
  10. Decreased levels of proteasome activity and proteasome expression in aging spinal cord.
    Neuroscience. 2000;98(1):149-56 PMID: 10858621
  11. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
    Science. 2001 Mar 23;291(5512):2423-8 PMID: 11264541
  12. Possible involvement of proteasome inhibition in aging: implications for oxidative stress.
    Mech Ageing Dev. 2000 Jan 24;113(1):61-70 PMID: 10708250
  13. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Hum Mol Genet. 1999 Apr;8(4):673-82 PMID: 10072437
  14. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2898-903 PMID: 10717003
  15. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
    Neuron. 1997 Dec;19(6):1147-50 PMID: 9427237
  16. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone.
    Hum Mol Genet. 1999 May;8(5):731-41 PMID: 10196362
  17. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4604-9 PMID: 10200309
  18. Huntington's disease: the challenge for cell biologists.
    Trends Cell Biol. 2000 Dec;10(12):531-6 PMID: 11121745
  19. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death.
    Hum Mol Genet. 2001 May 1;10(10):1039-48 PMID: 11331614
  20. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence.
    Nat Genet. 1994 Aug;7(4):525-30 PMID: 7951324
  21. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.
    J Neurosci. 1999 Apr 1;19(7):2522-34 PMID: 10087066
  22. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
    Cell. 1997 Aug 8;90(3):537-48 PMID: 9267033
  23. Impairment of the ubiquitin-proteasome system by protein aggregation.
    Science. 2001 May 25;292(5521):1552-5 PMID: 11375494
  24. Primary culture of identified neurons from the visual cortex of postnatal rats.
    J Neurosci. 1986 Oct;6(10):3044-60 PMID: 3760948
  25. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.
    J Neurosci. 1995 May;15(5 Pt 2):3775-87 PMID: 7751945
  26. Developmental regulation of type II calcium/calmodulin-dependent kinase isoforms in rat cerebellum.
    J Neurobiol. 1990 Dec;21(8):1262-73 PMID: 2177100
  27. Phosphorylation of a neuronal-specific beta-tubulin isotype.
    J Biol Chem. 1990 Aug 15;265(23):13949-54 PMID: 2199448
  28. Trinucleotide instability: a repeating theme in human inherited disorders.
    Annu Rev Med. 1996;47:201-9 PMID: 8712774
  29. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
    Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 PMID: 1319065
  30. Development of inhibitory synapses among striatal neurons in vitro.
    J Neurosci. 1989 Nov;9(11):3955-65 PMID: 2585061
  31. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.
    Cell. 2000 Mar 31;101(1):57-66 PMID: 10778856
  32. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8093-7 PMID: 10869421
  33. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8727-32 PMID: 10411943
  34. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat.
    Somat Cell Mol Genet. 1994 Jan;20(1):27-38 PMID: 8197474
  35. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.
    Nat Genet. 1998 Oct;20(2):198-202 PMID: 9771716
  36. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.
    Nat Genet. 2000 Sep;26(1):44-50 PMID: 10973246
  37. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.
    Mol Biol Cell. 2001 May;12(5):1393-407 PMID: 11359930
  38. Neuropathological classification of Huntington's disease.
    J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 PMID: 2932539
  39. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein.
    Hum Mol Genet. 2001 Jul 1;10(14):1441-8 PMID: 11448935
  40. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.
    Cell. 1997 Aug 8;90(3):549-58 PMID: 9267034
  41. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract.
    Hum Mol Genet. 2000 Jan 1;9(1):133-44 PMID: 10587588
  42. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.
    Neuron. 1999 Dec;24(4):879-92 PMID: 10624951
  43. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
    Cell. 1993 Mar 26;72(6):971-83 PMID: 8458085
  44. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.
    Nat Genet. 1998 Jun;19(2):148-54 PMID: 9620770
  45. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Hum Mol Genet. 2001 May 1;10(10):1049-59 PMID: 11331615
  46. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.
    Cell. 1998 Oct 2;95(1):41-53 PMID: 9778246
  47. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.
    Science. 1997 Sep 26;277(5334):1990-3 PMID: 9302293
  48. Genetic neurodegenerative diseases: the human illness and transgenic models.
    Science. 1998 Nov 6;282(5391):1079-83 PMID: 9804539
  49. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture.
    Methods Cell Biol. 1995;46:187-216 PMID: 7541884
  50. Huntington aggregates may not predict neuronal death in Huntington's disease.
    Ann Neurol. 1999 Dec;46(6):842-9 PMID: 10589536
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2001-11-15
Pages
8772-81
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC6762274
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]